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February 2016 Abstracts S19combined with platinum chemotherapy is speciﬁcally
indicated for treatment of non-squamous non-small cell
lung cancer (non-sq NSCLC). Pemetrexed is a folate-
analog metabolic inhibitor that disrupts folate-depen-
dent processes essential for cell replication. Pemetrexed
inhibits thymidylate synthase (TS), dihydrofolate
reductase (DHFR), and glycinamide ribonucleotide for-
myltransferase (GARFT), which are folate-dependent
enzymes involved in the de novo biosynthesis of
thymidine and purine nucleotides. Folate receptor alpha
(FRalpha) is a folate/antifolate transporter protein that
is overexpressed by a number of epithelial tumors. The
purpose of this study is to identify proteomic biomarkers
predictive of response to pemetrexed-based chemo-
therapy in non-sq NSCLC.
Methods: Patients with advanced non-sq NSCLC who
received pemetrexed-based chemotherapy at West
Virginia University from 2009 to 2014 were retro-
spectively identiﬁed. Formalin-ﬁxed, parafﬁn-
embedded tumor biopsies were laser microdissected,
solubilized, enzymatically digested and subjected to
quantitative proteomic analysis. A multiplexed,
selected reaction monitoring (SRM) mass spectrom-
etry (MS) assay was used to determine the absolute
levels of 46 different candidate proteomic markers,
including those in the folate receptor pathway. TS
analysis was also performed by IHC. The Kaplan-Meier
method and log-rank test were used in statistical
analysis of overall survival (OS) and progression-free
survival (PFS).
Results: The 74 patients included in the study had a
median follow-up of 26 months, a median OS of 16.6
months (95%CI: 11.6 - 43.4), and a median PFS of
9.61 months (95%CI: 8.43, 12.98). There were 65
patients who received pemetrexed-based regimen as a
ﬁrst line therapy and 9 patients as subsequent salvage
treatment. In a comparison between patients who
survived >24 months and < 8 months, there were no
signiﬁcant differences between the two groups in
terms of sex, age, ECOG performance status, TNM
stage at diagnosis, and smoking history. Among the 37
patients with sufﬁcient tumor specimens available for
multiplexed proteomic analysis, 30 biomarkers were
detected with varying levels of expression. Sixteen
additional biomarkers were undetectable. TS protein
expression was detected in by SRM in 2 patients and
by IHC in 32 patients (tumor staining>1); however,
TS IHC was not predictive of outcome (PFS-HR
ratio ¼ 1.06). Patients whose tumors expressed low
levels of GARFT protein (900 amol/mg; n¼7) had
statistically signiﬁcantly longer median PFS than
those whose tumors expressed high levels of
GARFT (>900 amol/mg; n¼30) (40.6 vs. 11.4 months;p ¼ 0.014). Patients with high FRalpha protein
expression (>1510 amol/mg, n¼9) had signiﬁcantly
longer median PFS than those with low FRalpha
expression (1510 amol/mg; n¼28) (>50 vs. 11.4
months; p¼ 0.021). Moreover, the 23 patients with
both high GARFT expression (>900 amol/mg) and low
FRalpha expression (1510 amol/mg) faired consid-
erably worse than the remainder of patients (median
PFS 10.1 vs. 40.6 months; p¼0.0003).
Conclusion: Multiplexed mass spectrometry-based pro-
teomics offers a feasible and promising approach for
tumor biomarker proﬁling and quantiﬁcation to predict
therapeutic response. Of note, our results show that
FRalpha and GARFT protein expression may be predic-
tive of response to pemetrexed-based treatment in pa-
tients with non-sq NSCLC. Further investigation is
needed to validate the utility of these biomarkers for
guiding personalized treatment decisions in clinical
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Introduction and objectives: Squamous lung cancer
(SQC) is a devastating disease for which the currently
available treatments are poorly effective. There are no
licensed targeted therapeutic agents. Improving the early
detection and chemoprevention of SQC, and identifying
novel and tractable therapeutic targets are key chal-
lenges to improving outcomes.
The development of model systems that recapitulate
the human disease will facilitate the development of new
therapeutic/chemopreventive agents and new insights
into the pathobiology of SQC.
SOX2 ampliﬁcation is a frequent genetic alteration in
squamous lung cancer. We have shown that ampliﬁca-
tion and overexpression of SOX2 is an early and
consistent event in the pathogenesis of this disease.
Our hypothesis is that deregulated expression of SOX2
is a key event in the initiation of bronchial dysplasia/
squamous carcinogenesis.
Our aims are:
1) To develop a novel 3D in vitro model of human
bronchial dysplasia that recapitulates the molecu-
lar and phenotypic characteristics of the in vivo
disease
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key initiating event in the pathogenesis of bronchial
dysplasia
3) To deﬁne the functional impact of SOX2
deregulation
Methods: We use lentiviral transduction and Cas9/
CRISPR editing genome to genetically modify immor-
talized human bronchial epithelial cells (HBECs); thus
creating a suite of cells with complex genotypes,
recapitulating the molecular lesions seen in the human
disease. Genetically manipulated HBECs are grown at
the air-liquid interface on a stromal equivalent with
embedded pulmonary ﬁbroblasts – an organotypic
system (OTC). We use an inducible construct so that
SOX2 is only deregulated in HBECs that are already
conﬂuent at the air-liquid interface. OTCs are pro-
cessed for downstream analyses including immuno-
histochemistry, cell cycle analyses, RNA- Seq and
ChIP-Seq.
Results: We have developed a novel model that re-
capitulates human bronchial dysplasia. SOX2 deregula-
tion does not impact upon cell cycle progression or cell
population expansion in standard tissue culture condi-
tions. However, in the organotypic system described
above, overexpression of SOX2 in conﬂuent HBECs at the
air-liquid interface initiates focal dysplastic outgrowths
from the monolayer that exhibit histological character-
istics of high-grade human bronchial dysplasia.
Combining SOX2 activation with the loss of TP53
markedly potentiates the dysplastic phenotype, recapit-
ulating the likely in vivo sequence of molecular events.
SOX2 overexpression alters key cell signaling pathways
(MAPK and PI3K/AKT) in a pattern reﬂecting those seen
in squamous lung cancer.
Recent RNA- and CHiP-Seq analyses suggest SOX2
regulates a series of target genes implicated in cell
migration and metastasis, key hallmarks of malignant
progression. These results are currently being validated
and functional validation planned.
Conclusions: In the appropriate molecular and micro-
environmental context acute deregulation of SOX2 initi-
ates and drives bronchial dysplasia in immortalized
human bronchial epithelial cells. This work is consistent
with many others in which the microenvironment has
been shown to be as critical as cell intrinsic pathways in
the development of cancer.
This model system is well suited for screening novel
therapeutics and chemoprevention agents as well
advancing our understanding of the pathobiology of SQC.
Further work is underway to evaluate the functional
impact of SOX2 deregulation in this short-term model of
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Background: E74-like factor 3 (ELF3) is a member of
the ETS family of transcription factors that was recently
identiﬁed as an important target of SMAD4 in a mouse
model of lung tumorigenesis. ELF3 is also a described
oncogene in breast and prostate cancer; however, little is
known about the function of ELF3 in human lung cancer
and the dependence of ELF3 overexpression on SMAD4
loss. Here we investigate this dependence, as well as
alternative genetic and epigenetic mechanisms of ELF3
overexpression in two independent cohorts of lung
adenocarcinoma (AC).
Methods: DNA copy number, promoter methylation,
and mRNA expression data was queried in two co-
horts of lung AC: BC Cancer Research Centre (n¼83)
and The Cancer Genome Atlas (TCGA) (n¼551). Mu-
tation information was only available for the TCGA
cohort. GISTIC 2.0 was used to determine signiﬁcantly
focally ampliﬁed regions from segmentation data.
Stable shRNA knock-down of ELF3 was performed in a
panel of AC cell lines with high ELF3 expression.
Similarly, expression of ELF3 in HBECs was mediated
by lentiviral delivery of an overexpression vector. Cell
viability was assessed by MTT assay, while prolifera-
tion was assessed by BrdU assay and colony formation
assay. Tumor growth was monitored in vivo following
ﬂank injections of isogenic cell lines into NOD-SCID
mice. ELF3 cellular localization in lung AC cell lines
was assessed by western blot and immunoﬂuores-
cence, and in tumors by immunohistochemistry. As-
sociations with clinical features were determined by
Fisher’s tests, while survival analyses were performed
using the log-rank method.
Results: ELF3 overexpression occurred in over two-
thirds of lung adenocarcinomas and was not depen-
dent on SMAD4 copy number loss or underexpression.
In fact, tumors with high expression of ELF3 were
more likely to recur than those with SMAD4 loss
indicating divergent biological functions. ELF3 over-
expression was frequently selected-for at the DNA
